LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response.
暂无分享,去创建一个
T. He | W. Fan | yang-xin fu | Jinjia Chang | Huilin Zheng | Weibin Zou
[1] Mark T. W. Ebbert,et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.
[2] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[3] Hiroyuki Tomita,et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. , 2011, Cancer cell.
[4] H. Schreiber,et al. Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase , 2010, The Journal of experimental medicine.
[5] J. Medin,et al. Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming. , 2010, Cancer research.
[6] M. Greene,et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. , 2010, Cancer cell.
[7] W. Woodward,et al. Mesenchymal Stem Cells Promote Mammosphere Formation and Decrease E-Cadherin in Normal and Malignant Breast Cells , 2010, PloS one.
[8] Cathrin Brisken,et al. Epithelial‐Mesenchymal Transition‐Derived Cells Exhibit Multilineage Differentiation Potential Similar to Mesenchymal Stem Cells , 2010, Stem cells.
[9] Z. Werb,et al. Tumors as organs: complex tissues that interface with the entire organism. , 2010, Developmental cell.
[10] Y. DeClerck,et al. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment , 2010, Cancer and Metastasis Reviews.
[11] S. Raiden,et al. Mouse Bone Marrow-Derived Mesenchymal Stromal Cells Turn Activated Macrophages into a Regulatory-Like Profile , 2010, PloS one.
[12] R. Romieu-Mourez,et al. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. , 2009, Blood.
[13] D. Davies,et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. , 2009, Cancer research.
[14] D. Bonnet,et al. Isolation, culture, and differentiation potential of mouse marrow stromal cells. , 2008, Current protocols in stem cell biology.
[15] H. Friess,et al. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma , 2008, British Journal of Cancer.
[16] B. Quesnel. Tumor dormancy and immunoescape , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[17] M. Yarmush,et al. Bone Marrow‐Derived Mesenchymal Stem Cells Ameliorate Autoimmune Enteropathy Independently of Regulatory T Cells , 2008, Stem cells.
[18] D. Martineau,et al. Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. , 2008, Cancer research.
[19] M. Schwaiger,et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. , 2008, Cancer cell.
[20] yang-xin fu,et al. Targeting tumors with LIGHT to generate metastasis-clearing immunity. , 2008, Cytokine & growth factor reviews.
[21] W. Woodward,et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. , 2007, Cancer research.
[22] A. Nauta,et al. Immunomodulatory properties of mesenchymal stromal cells. , 2007, Blood.
[23] J. Aguirre-Ghiso,et al. Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.
[24] Ross Tubo,et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.
[25] M. Kerin,et al. Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells , 2007, Clinical Cancer Research.
[26] Youjin Lee,et al. Targeting the Primary Tumor to Generate CTL for the Effective Eradication of Spontaneous Metastases1 , 2007, The Journal of Immunology.
[27] R. Weichselbaum,et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells , 2007, The Journal of experimental medicine.
[28] A. Uccelli,et al. Immunoregulatory function of mesenchymal stem cells , 2006, European journal of immunology.
[29] S. Nadri,et al. Murine mesenchymal stem cells isolated by low density primary culture system , 2006, Development, growth & differentiation.
[30] M. Loeffler,et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.
[31] Anoop P. Patel,et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. , 2006, Blood.
[32] M. Raffeld,et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma , 2006, The Journal of experimental medicine.
[33] H. Schreiber,et al. The role of stroma in immune recognition and destruction of well-established solid tumors. , 2006, Current opinion in immunology.
[34] J. Galipeau,et al. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. , 2006, Blood.
[35] David Zurakowski,et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.
[36] H. Schreiber,et al. Bystander elimination of antigen loss variants in established tumors , 2004, Nature Medicine.
[37] Youjin Lee,et al. Priming of naive T cells inside tumors leads to eradication of established tumors , 2004, Nature Immunology.
[38] F. Djouad,et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. , 2003, Blood.
[39] Lindolfo da Silva Meirelles,et al. Murine marrow‐derived mesenchymal stem cell: isolation, in vitro expansion, and characterization , 2003, British journal of haematology.
[40] S. Granger,et al. LIGHT-HVEM signaling and the regulation of T cell-mediated immunity. , 2003, Cytokine & growth factor reviews.
[41] Elizabeth Simpson,et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.
[42] Y. Zhai,et al. LIGHT, a new member of the TNF superfamily. , 2002, Journal of biological regulators and homeostatic agents.
[43] Osamu Yoshie,et al. Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. , 2002, Immunity.
[44] K. Tamada,et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. , 2001, The Journal of clinical investigation.
[45] J. Bluestone,et al. Reversal of Spontaneous Autoimmune Insulitis in Nonobese Diabetic Mice by Soluble Lymphotoxin Receptor , 2001, The Journal of experimental medicine.
[46] G. Zhu,et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway , 2000, Nature Medicine.
[47] L. Williams,et al. Mice Lacking Expression of Secondary Lymphoid Organ Chemokine Have Defects in Lymphocyte Homing and Dendritic Cell Localization , 1999, The Journal of experimental medicine.
[48] D. Gisselsson,et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[49] M. Soleimani,et al. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow , 2009, Nature Protocols.
[50] K. Kang,et al. Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. , 2009, Cytotherapy.
[51] C. Ware,et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. , 1998, Immunity.